COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN TAIWAN

被引：1
|
作者：
Zou, D. [1 ]
Kendall, R. [1 ]
Lin, Q. [2 ]
Huang, Y. [2 ]
Tieng, J. [3 ]
Tseng, J. [3 ]
Sajosi, P. [4 ]
机构：
[1] ICON Plc, Vancouver, BC, Canada
[2] Kantar Hlth, Taipei, Taiwan
[3] Takeda Pharmaceut Taiwan, Taipei, Taiwan
[4] Takeda Pharmaceut Int AG, Zurich, Switzerland
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.08.705
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CE2
引用
收藏
页码：A811 / A811
页数：1
相关论文
共 50 条
  • [11] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    Kenichi Ishizawa
    Tomoko Yanai
    Advances in Therapy, 2019, 36 : 2679 - 2696
  • [12] BRENTUXIMAB VEDOTIN DESENSITIZATION IN A FEMALE WITH RELAPSED, REFRACTORY, ANAPLASTIC LARGE-CELL LYMPHOMA (ALCL)
    Qamar, N.
    Cho, S.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2012, 109 (05) : A68 - A68
  • [13] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Senter, Peter D.
    Sievers, Eric L.
    NATURE BIOTECHNOLOGY, 2012, 30 (07) : 631 - 637
  • [14] Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
    Shustov, Andrei R.
    Advani, Ranjana
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey
    Ramachandren, Radhakrishnan
    Fanale, Michelle A.
    Connors, Joseph M.
    Yang, Yin
    Sievers, Eric L.
    Kennedy, Dana A.
    Pro, Barbara
    BLOOD, 2010, 116 (21) : 423 - 424
  • [15] BRENTUXIMAB VEDOTIN PLUS CHP IN FRONTLINE SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (SALCL): ADJUSTED ESTIMATES OF EFFICACY AND COST-EFFECTIVENESS REMOVING THE EFFECTS OF RETREATMENT WITH BRENTUXIMAB VEDOTIN
    Cranmer, H.
    Trueman, D.
    Woodcock, F.
    Evers, E.
    Podkonjak, T.
    VALUE IN HEALTH, 2020, 23 : S431 - S431
  • [16] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Peter D Senter
    Eric L Sievers
    Nature Biotechnology, 2012, 30 : 631 - 637
  • [17] Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature
    Zinzani, P. L.
    Sasse, S.
    Radford, J.
    Shonukan, O.
    Bonthapally, V.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (03) : 359 - 369
  • [18] Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
    Patel, Kishan K.
    Isufi, Iris
    Kothari, Shalin
    Foss, Francine
    Huntington, Scott
    LEUKEMIA & LYMPHOMA, 2020, 61 (14) : 3387 - 3394
  • [19] Brentuximab vedotin in anaplastic large cell lymphoma
    Skarbnik, Alan P. Z.
    Smith, Mitchell R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 633 - 639
  • [20] Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin
    Chihara, Dai
    Wong, Shannon
    Feldman, Tatyana
    Fanale, Michelle A.
    Sanchez, Larysa
    Connors, Joseph M.
    Savage, Kerry J.
    Oki, Yasuhiro
    HEMATOLOGICAL ONCOLOGY, 2019, 37 (01) : 35 - 38
12345